Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Diabetic Foot Ulcer
Interventions: TWO2 Device, Placebo Device; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Phoenix, Arizona • Vacaville, California • Washington D.C., District of Columbia + 6 more

Conditions: Psoriasis
Interventions: PF-06826647 or Placebo, PF-06826647; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 13 more

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more

Conditions: Cough, Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 57
States / cities: Foley, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more

Conditions: Total Knee Arthroplasty
Interventions: Placebo, Duloxetine 60mg; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 25 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more

Conditions: Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)
Interventions: Nicotinamide, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metabolic Syndrome, Insulin Resistance, DNA Damage
Interventions: Blueberry Powder, Placebo; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Precancerous Condition
Interventions: liposomal T4N5 lotion; Drug
Lead sponsor: Applied Genetics; Industry
Eligibility: 2 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 7
States / cities: Miami Beach, Florida • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more

Conditions: Pancreatic Insufficiency, Cystic Fibrosis, Digestive System Diseases, Lung Diseases, Respiratory Tract Diseases
Interventions: Burlulipase, Placebo (Caramel in sterile water); Drug
Lead sponsor: Nordmark Arzneimittel GmbH & Co. KG; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 9
States / cities: Jacksonville, Florida • Pensacola, Florida • Iowa City, Iowa + 6 more

Conditions: Tuberous Sclerosis Complex
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more

Conditions: Hernia, Ventral
Interventions: bupivacaine, On-Q PainBuster pump; Drug · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bilateral Sensorineural Hearing Loss
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Oxytocin nasal spray, Placebo nasal spray; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Covid19
Interventions: Telmisartan Oral Product, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: PTSD
Interventions: Quetiapine, Placebo; Drug
Lead sponsor: Ralph H. Johnson VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Charleston, South Carolina

Conditions: Atopic Dermatitis, Psoriasis
Interventions: YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily; Drug
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Multifocal Motor Neuropathy
Interventions: ARGX-117, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Scottsdate, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Cocaine Abuse
Interventions: Galantamine, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Substance Abuse
Interventions: atomoxetine, placebo; Drug
Lead sponsor: Sharon Walsh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 2 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Stockton, California • Tustin, California

Conditions: Hyperhidrosis
Interventions: glycopyrronium Topical Wipes, Vehicle; Drug · Other
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 9 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Mobile, Alabama • Encinitas, California • San Diego, California + 18 more

Conditions: Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions: Azficel-T (autologous fibroblasts), Placebo; Biological · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Stanford, California • New York, New York

Conditions: Coronary Disease
Interventions: Placebo Oral Tablet, Atorvastatin 80mg, Screening; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

Oxytocin and Cognitive Control in Adult ADHD

INvestigating TELmisartin Study

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Study of Glycopyrronium in Axillary Hyperhydrosis

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

Effects of Atorvastatin on Myonecrosis